Taiho Ventures and SR One co-led a series A round that will fund the early clinical progress of Dren's cancer and protein-depletion drug candidates.
Pharmaceutical firms Taiho and GlaxoSmithKline have co-led a $60m series A round for US-headquartered protein-engineering technology developer Dren Bio through corporate venturing subsidiaries Taiho Ventures and SR One.
The round included Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as Mission BioCapital, BVF Partners, HBM Healthcare Investments and 8VC.
Dren is working on technology intended to deplete cells and protein aggregates that cause disease. It is predominantly targeting…
